Effect of Leflunomide Use on 68Ga-DOTATATE Biodistribution in a Case With Neuroendocrine Tumor

A 58-year-old man who underwent surgery for a well-differentiated neuroendocrine tumor of pancreatic origin was evaluated with 68Ga-DOTATATE PET/CT imaging in the follow-up period. After PET/CT findings consistent with disease remission, the patient was started on leflunomide treatment with the diag...

Full description

Saved in:
Bibliographic Details
Published in:Clinical nuclear medicine 2023-02, Vol.48 (2), p.e71-e73
Main Authors: Tatar, Gamze, Beyhan, Ediz, Arslan, Esra, Ergül, Nurhan, Çermik, Tevfik Fikret
Format: Article
Language:English
Subjects:
Humans
Leflunomide - therapeutic use
Male
Middle Aged
Neuroendocrine Tumors - pathology
Organometallic Compounds - therapeutic use
Positron Emission Tomography Computed Tomography - methods
Tissue Distribution
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c186t-1e5b57bc48115b38732695e4dc555bd7778a9535450a2625679659d4727017203
container_end_page e73
container_issue 2
container_start_page e71
container_title Clinical nuclear medicine
container_volume 48
creator Tatar, Gamze
Beyhan, Ediz
Arslan, Esra
Ergül, Nurhan
Çermik, Tevfik Fikret
description A 58-year-old man who underwent surgery for a well-differentiated neuroendocrine tumor of pancreatic origin was evaluated with 68Ga-DOTATATE PET/CT imaging in the follow-up period. After PET/CT findings consistent with disease remission, the patient was started on leflunomide treatment with the diagnosis of rheumatoid arthritis. The patient received leflunomide for 6 months. Then, 68Ga-DOTATATE PET/CT scan was repeated to evaluate the primary disease outcome. Besides the disease remission, we also observed alterations in DOTATATE uptakes of some tissues and organs. In this case, we present the changes in 68Ga-DOTATATE PET/CT scan findings after leflunomide use.
doi_str_mv 10.1097/RLU.0000000000004517
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2761985220</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2761985220</sourcerecordid><originalsourceid>FETCH-LOGICAL-c186t-1e5b57bc48115b38732695e4dc555bd7778a9535450a2625679659d4727017203</originalsourceid><addsrcrecordid>eNpdkE1PwzAMhiMEYmPwDxDKkUtHPuqkOY5tDKSKSWgTN6q0TUVQ24ykPfDvKWwghH3wwc9rSw9Cl5RMKVHy5indTsmfioHKIzSmwEVEGFPHaEy44JGSgo3QWQhvhFBBRXyKRlwIIrkUY_SyrCpTdNhVODVV3beusaXB22Cwa7FIVjparDezoZf41rrShs7bvO_ssLUt1niuB_TZdq_40fTembZ0hbetwZu-cf4cnVS6DubiMCdoe7fczO-jdL16mM_SqKCJ6CJqIAeZF3FCKeQ8kZwJBSYuCwDISyllohVwiIFoJhgIqQSoMpZMEioZ4RN0vb-78-69N6HLGhsKU9e6Na4PGZOCqgTYNxrv0cK7ELypsp23jfYfGSXZl9lsMJv9NzvErg4f-rwx5W_oRyX_BEGocF0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2761985220</pqid></control><display><type>article</type><title>Effect of Leflunomide Use on 68Ga-DOTATATE Biodistribution in a Case With Neuroendocrine Tumor</title><source>LWW_医学期刊</source><creator>Tatar, Gamze ; Beyhan, Ediz ; Arslan, Esra ; Ergül, Nurhan ; Çermik, Tevfik Fikret</creator><creatorcontrib>Tatar, Gamze ; Beyhan, Ediz ; Arslan, Esra ; Ergül, Nurhan ; Çermik, Tevfik Fikret</creatorcontrib><description>A 58-year-old man who underwent surgery for a well-differentiated neuroendocrine tumor of pancreatic origin was evaluated with 68Ga-DOTATATE PET/CT imaging in the follow-up period. After PET/CT findings consistent with disease remission, the patient was started on leflunomide treatment with the diagnosis of rheumatoid arthritis. The patient received leflunomide for 6 months. Then, 68Ga-DOTATATE PET/CT scan was repeated to evaluate the primary disease outcome. Besides the disease remission, we also observed alterations in DOTATATE uptakes of some tissues and organs. In this case, we present the changes in 68Ga-DOTATATE PET/CT scan findings after leflunomide use.</description><identifier>ISSN: 0363-9762</identifier><identifier>EISSN: 1536-0229</identifier><identifier>DOI: 10.1097/RLU.0000000000004517</identifier><identifier>PMID: 36607376</identifier><language>eng</language><publisher>United States</publisher><subject>Humans ; Leflunomide - therapeutic use ; Male ; Middle Aged ; Neuroendocrine Tumors - pathology ; Organometallic Compounds - therapeutic use ; Positron Emission Tomography Computed Tomography - methods ; Tissue Distribution</subject><ispartof>Clinical nuclear medicine, 2023-02, Vol.48 (2), p.e71-e73</ispartof><rights>Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c186t-1e5b57bc48115b38732695e4dc555bd7778a9535450a2625679659d4727017203</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36607376$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tatar, Gamze</creatorcontrib><creatorcontrib>Beyhan, Ediz</creatorcontrib><creatorcontrib>Arslan, Esra</creatorcontrib><creatorcontrib>Ergül, Nurhan</creatorcontrib><creatorcontrib>Çermik, Tevfik Fikret</creatorcontrib><title>Effect of Leflunomide Use on 68Ga-DOTATATE Biodistribution in a Case With Neuroendocrine Tumor</title><title>Clinical nuclear medicine</title><addtitle>Clin Nucl Med</addtitle><description>A 58-year-old man who underwent surgery for a well-differentiated neuroendocrine tumor of pancreatic origin was evaluated with 68Ga-DOTATATE PET/CT imaging in the follow-up period. After PET/CT findings consistent with disease remission, the patient was started on leflunomide treatment with the diagnosis of rheumatoid arthritis. The patient received leflunomide for 6 months. Then, 68Ga-DOTATATE PET/CT scan was repeated to evaluate the primary disease outcome. Besides the disease remission, we also observed alterations in DOTATATE uptakes of some tissues and organs. In this case, we present the changes in 68Ga-DOTATATE PET/CT scan findings after leflunomide use.</description><subject>Humans</subject><subject>Leflunomide - therapeutic use</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Neuroendocrine Tumors - pathology</subject><subject>Organometallic Compounds - therapeutic use</subject><subject>Positron Emission Tomography Computed Tomography - methods</subject><subject>Tissue Distribution</subject><issn>0363-9762</issn><issn>1536-0229</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNpdkE1PwzAMhiMEYmPwDxDKkUtHPuqkOY5tDKSKSWgTN6q0TUVQ24ykPfDvKWwghH3wwc9rSw9Cl5RMKVHy5indTsmfioHKIzSmwEVEGFPHaEy44JGSgo3QWQhvhFBBRXyKRlwIIrkUY_SyrCpTdNhVODVV3beusaXB22Cwa7FIVjparDezoZf41rrShs7bvO_ssLUt1niuB_TZdq_40fTembZ0hbetwZu-cf4cnVS6DubiMCdoe7fczO-jdL16mM_SqKCJ6CJqIAeZF3FCKeQ8kZwJBSYuCwDISyllohVwiIFoJhgIqQSoMpZMEioZ4RN0vb-78-69N6HLGhsKU9e6Na4PGZOCqgTYNxrv0cK7ELypsp23jfYfGSXZl9lsMJv9NzvErg4f-rwx5W_oRyX_BEGocF0</recordid><startdate>20230201</startdate><enddate>20230201</enddate><creator>Tatar, Gamze</creator><creator>Beyhan, Ediz</creator><creator>Arslan, Esra</creator><creator>Ergül, Nurhan</creator><creator>Çermik, Tevfik Fikret</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20230201</creationdate><title>Effect of Leflunomide Use on 68Ga-DOTATATE Biodistribution in a Case With Neuroendocrine Tumor</title><author>Tatar, Gamze ; Beyhan, Ediz ; Arslan, Esra ; Ergül, Nurhan ; Çermik, Tevfik Fikret</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c186t-1e5b57bc48115b38732695e4dc555bd7778a9535450a2625679659d4727017203</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Humans</topic><topic>Leflunomide - therapeutic use</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Neuroendocrine Tumors - pathology</topic><topic>Organometallic Compounds - therapeutic use</topic><topic>Positron Emission Tomography Computed Tomography - methods</topic><topic>Tissue Distribution</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tatar, Gamze</creatorcontrib><creatorcontrib>Beyhan, Ediz</creatorcontrib><creatorcontrib>Arslan, Esra</creatorcontrib><creatorcontrib>Ergül, Nurhan</creatorcontrib><creatorcontrib>Çermik, Tevfik Fikret</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical nuclear medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tatar, Gamze</au><au>Beyhan, Ediz</au><au>Arslan, Esra</au><au>Ergül, Nurhan</au><au>Çermik, Tevfik Fikret</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effect of Leflunomide Use on 68Ga-DOTATATE Biodistribution in a Case With Neuroendocrine Tumor</atitle><jtitle>Clinical nuclear medicine</jtitle><addtitle>Clin Nucl Med</addtitle><date>2023-02-01</date><risdate>2023</risdate><volume>48</volume><issue>2</issue><spage>e71</spage><epage>e73</epage><pages>e71-e73</pages><issn>0363-9762</issn><eissn>1536-0229</eissn><abstract>A 58-year-old man who underwent surgery for a well-differentiated neuroendocrine tumor of pancreatic origin was evaluated with 68Ga-DOTATATE PET/CT imaging in the follow-up period. After PET/CT findings consistent with disease remission, the patient was started on leflunomide treatment with the diagnosis of rheumatoid arthritis. The patient received leflunomide for 6 months. Then, 68Ga-DOTATATE PET/CT scan was repeated to evaluate the primary disease outcome. Besides the disease remission, we also observed alterations in DOTATATE uptakes of some tissues and organs. In this case, we present the changes in 68Ga-DOTATATE PET/CT scan findings after leflunomide use.</abstract><cop>United States</cop><pmid>36607376</pmid><doi>10.1097/RLU.0000000000004517</doi></addata></record>
fulltext fulltext
identifier ISSN: 0363-9762
ispartof Clinical nuclear medicine, 2023-02, Vol.48 (2), p.e71-e73
issn 0363-9762
1536-0229
language eng
recordid cdi_proquest_miscellaneous_2761985220
source LWW_医学期刊
subjects Humans
Leflunomide - therapeutic use
Male
Middle Aged
Neuroendocrine Tumors - pathology
Organometallic Compounds - therapeutic use
Positron Emission Tomography Computed Tomography - methods
Tissue Distribution
title Effect of Leflunomide Use on 68Ga-DOTATATE Biodistribution in a Case With Neuroendocrine Tumor
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T15%3A36%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effect%20of%20Leflunomide%20Use%20on%2068Ga-DOTATATE%20Biodistribution%20in%20a%20Case%20With%20Neuroendocrine%20Tumor&rft.jtitle=Clinical%20nuclear%20medicine&rft.au=Tatar,%20Gamze&rft.date=2023-02-01&rft.volume=48&rft.issue=2&rft.spage=e71&rft.epage=e73&rft.pages=e71-e73&rft.issn=0363-9762&rft.eissn=1536-0229&rft_id=info:doi/10.1097/RLU.0000000000004517&rft_dat=%3Cproquest_cross%3E2761985220%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c186t-1e5b57bc48115b38732695e4dc555bd7778a9535450a2625679659d4727017203%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2761985220&rft_id=info:pmid/36607376&rfr_iscdi=true